TGTX Stock Analysis: TG Therapeutics | NASDAQ

BRIUMVI, Anti-CD20, BTK Inhibitor, Bispecific Antibody

Total Rating 51

Safety 32

Buy Signal 0.03

Biotechnology
Industry Rotation: -21.3

Market Cap: 7.53B
Avg Turnover: 113M

Risk 3d forecast

Volatility59.0%

VaR 5^th Pctl8.69%

VaR vs Median-8.72%

Reward TTM

Sharpe Ratio1.55

Rel. Str. IBD91.5

Rel. Str. Peer Group64.8

Character TTM

Beta0.503

Beta Downside-0.509

Hurst Exponent0.447

Drawdowns 3y

Max DD42.06%

CAGR/Max DD1.51

CAGR/Mean DD3.48

EPS (Earnings per Share)

Last SUE: -3.59
Qual. Beats: -3

Revenue

Rev. CAGR: 62.95%
Rev. Trend: 97.3%

Last SUE: 2.18
Qual. Beats: 1

Warnings

Earnings Expected To Drop (P/E To P/E Forward)

Beneish M-Score Likely Earnings Manipulation

Tailwinds

Rs Leader

Seasonality 11.6 years of data

Jan +0.9% 17

Feb +3.4% 8

Mar +1.0% 17

Apr +0.4% 7

May -7.8% 28

Jun -3.1% 5

Jul -5.5% 20

Aug +5.3% 12

Sep -7.3% 27

Oct -5.6% 25

Nov +9.5% 38

Dec +7.7% 2

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: TGTX TG Therapeutics

TG Therapeutics (NASDAQ: TGTX) is a U.S.-based commercial stage biopharmaceutical company incorporated in 1993 and headquartered in Morrisville, North Carolina. The company focuses on acquiring, developing, and commercializing novel therapies for B-cell mediated diseases, serving markets in the United States and internationally. Its lead marketed product is BRIUMVI, an anti-CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The companys development pipeline centers on B-cell and immune-targeting mechanisms. It includes Ublituximab IV, a glycoengineered anti-CD20 monoclonal antibody for relapsing MS; TG-1701, an oral covalent Brutons tyrosine kinase (BTK) inhibitor; and TG-1801, a bispecific antibody targeting both CD47 and CD19. Anti-CD20 antibodies have become a cornerstone class in the treatment of multiple sclerosis and other autoimmune conditions, while BTK inhibitors represent an active area of drug development in immunology and oncology. The company also maintains a broader research pipeline of investigational medicines.

TG Therapeutics supplements its internal R&D with licensing arrangements, holding agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Jiangsu Hengrui Medicine Co. Such partnerships are a common strategy for mid-sized biotechnology companies seeking to broaden their pipelines and geographic reach without bearing full development costs.

Headlines to Watch Out For

BRIUMVI sales accelerate in relapsing multiple sclerosis market
Competition from Ocrevus and Kesimpta pressures CD20 market share
TG-1701 BTK inhibitor pipeline data readout approaches

Piotroski VR-10 (Strict) 5.0

Net Income: 441.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.00 > 0.02 and ΔFCF/TA 8.40 > 1.0
NWC/Revenue: 109.7% < 20% (prev 108.4%; Δ 1.34% < -1%)
CFO/TA -0.00 > 3% & CFO -18.0k > Net Income 441.5m
Net Debt (211.2m) to EBITDA (136.6m): 1.55 < 3
Current Ratio: 4.27 > 1.5 & < 3
Outstanding Shares: last quarter (157.3m) vs 12m ago -3.25% < -2%
Gross Margin: 82.36% > 18% (prev 86.96%; Δ -4.59% > 0.5%)
Asset Turnover: 68.27% > 50% (prev 64.63%; Δ 3.65% > 0%)
Interest Coverage Ratio: 3.64 > 6 (EBIT TTM 136.3m / Interest Expense TTM 37.5m)

Altman Z'' 2.81

A: 0.53 (Total Current Assets 1.15b - Total Current Liabilities 268.5m) / Total Assets 1.64b
B: -0.64 (Retained Earnings -1.05b / Total Assets 1.64b)
C: 0.12 (EBIT TTM 136.3m / Avg Total Assets 1.17b)
D: 0.58 (Book Value of Equity 604.1m / Total Liabilities 1.04b)
Altman-Z'' = 2.81 = A

Beneish M 0.87

DSRI: 0.99 (Receivables 401.6m/231.5m, Revenue 799.5m/454.1m)
GMI: 1.06 (GM 86.96% / 82.36%)
AQI: 6.53 (AQ_t 0.30 / AQ_t-1 0.05)
SGI: 1.76 (Revenue 799.5m / 454.1m)
TATA: 0.27 (NI 441.5m - CFO -18.0k) / TA 1.64b)
Beneish M = 0.87 (Cap -4..+1) = D

What is the price of TGTX shares?

As of August 12, 2026, the stock is trading at USD 49.90 with a total of 1,500,777 shares traded. Over the past week, the price has changed by +2.39%, over one month by -9.29%, over three months by +15.67% and over the past year by +89.09%.

Current recommended Stop Loss: 47.20 (which is 5.4% or 1.1 ATR below the current price).

Is TGTX a buy, sell or hold?

TG Therapeutics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy TGTX.

StrongBuy: 6
Buy: 1
Hold: 1
Sell: 1
StrongSell: 0

What are the forecasts/targets for the TGTX price?

Analysts Target Price	77.8	56%

TG Therapeutics (TGTX) - Fundamental Data Overview as of 12 August 2026

Market Cap USD = 7.53b (7.53b USD * 1.0 USD.USD)
P/E Trailing = 18.2074
P/E Forward = 61.3497
P/S = 9.4124
P/B = 12.6138
P/EG = 1.6144
Revenue TTM = 799.5m USD
EBIT TTM = 136.3m USD
EBITDA TTM = 136.6m USD
Long Term Debt = 745.4m USD (from longTermDebt, last quarter)
Short Term Debt = 1.91m USD (from shortTermDebt, last quarter)
Debt = 763.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 9.05m
Net Debt = 211.2m USD (calculated: Debt 763.5m - CCE 552.2m)
Enterprise Value = 7.74b USD (7.53b + Debt 763.5m - CCE 552.2m)
Interest Coverage Ratio = 3.64 (Ebit TTM 136.3m / Interest Expense TTM 37.5m)
EV/FCF = -1000.0x (Enterprise Value 7.74b / FCF TTM -560k)
FCF Yield = -0.01% (FCF TTM -560k / Enterprise Value 7.74b)
FCF Margin = -0.07% (FCF TTM -560k / Revenue TTM 799.5m)
Net Margin = 55.22% (Net Income TTM 441.5m / Revenue TTM 799.5m)
Gross Margin = 82.36% ((Revenue TTM 799.5m - Cost of Revenue TTM 141.0m) / Revenue TTM)
Gross Margin QoQ = 82.86% (prev 83.65%)
Tobins Q-Ratio = 4.72 (Enterprise Value 7.74b / Total Assets 1.64b)
Interest Expense / Debt = 4.91% (Interest Expense 37.5m / Debt 763.5m)
Taxrate = 23.97% (2.45m / 10.2m)
NOPAT = 103.7m (EBIT 136.3m * (1 - 23.97%))
Current Ratio = 4.27 (Total Current Assets 1.15b / Total Current Liabilities 268.5m)
Debt / Equity = 1.26 (Debt 763.5m / totalStockholderEquity, last quarter 604.1m)
Debt / EBITDA = 1.55 (Net Debt 211.2m / EBITDA 136.6m)
Debt / FCF = -377.2 (out of range, set to none) (Net Debt 211.2m / FCF TTM -560k)
Total Stockholder Equity = 610.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 37.70% (Net Income 441.5m / Total Assets 1.64b)
RoE = 72.30% (Net Income TTM 441.5m / Total Stockholder Equity 610.6m)
RoCE = 10.05% (EBIT 136.3m / Capital Employed (Equity 610.6m + L.T.Debt 745.4m))
RoIC = 7.78% (NOPAT 103.7m / Invested Capital 1.33b)
WACC = 7.38% (E(7.53b)/V(8.29b) * Re(7.75%) + D(763.5m)/V(8.29b) * Rd(4.91%) * (1-Tc(0.24)))
Discount Rate = 7.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 38.39 | Cagr: 3.30%
[DCF] Fair Price = unknown (Cash Flow -560k)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -3.59 | # QB: -3
Revenue Correlation: 97.31 | Revenue CAGR: 62.95% | SUE: 2.18 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.27 | Chg30d=-36.58% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=0.95 | Chg30d=-37.71% | Revisions=+0% | GrowthEPS=-65.7% | GrowthRev=+55.8%
EPS next Year (2027-12-31): EPS=2.97 | Chg30d=-1.28% | Revisions=+40% | GrowthEPS=+212.8% | GrowthRev=+37.3%
[Analyst] Revisions Ratio: +22% (up=4, down=2)